Niagen Bioscience
Builds Niagen-based supplements, ingredients, and clinical NAD+ channels.
Something off on this page? Send us feedback.
Profile
Sells Tru Niagen supplements, Niagen ingredients, and prescription-channel Niagen access. The current business is concentrated around NAD+ science after exiting the legacy reference-standards operation.
Built around Niagen, a proprietary nicotinamide riboside ingredient used to support NAD+ biology. The main commercial lines are Tru Niagen supplements, food-grade Niagen supplied to product makers, and pharmaceutical-grade Niagen supplied into prescription and compounding channels.
Sales are concentrated in consumer supplements and ingredient supply, with international distribution through partners and online channels. Pharmaceutical work remains a development activity rather than a commercial drug franchise.
Current execution depends on scientific credibility, patent protection, supplement and compounding regulation, product labeling discipline, and continued demand for Tru Niagen after the reference-standards divestiture.
Company facts
Key statistics
Year to date −47.3% · Average volume (30d) 638.2K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 5, 2026 | Roth Capital | Reiterate | Buy | $10 | |
| May 11, 2026 | H.C. Wainwright | Target | $11 | ||
| May 5, 2026 | Canaccord Genuity | Reiterate | Buy | $14 | $10 |
| Nov 5, 2025 | Canaccord Genuity | Reiterate | Buy | $14 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $0.01 | $0.01 | +20.0% | $30.5M | $29.8M | −2.4% | −14.70% |
| May 6, 2026Q1 FY26 | $0.06 | $0.07 | +16.7% | $31.0M | $31.5M | +1.4% | −15.69% |
| Mar 4, 2026Q4 FY25 | $0.02 | $0.03 | +50.0% | $31.7M | $33.8M | +6.7% | +3.24% |
| Nov 4, 2025Q3 FY25 | $0.02 | $0.05 | +233.3% | $31.1M | $34.0M | +9.3% | −1.01% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $30.5M | $31.1M | $34.0M | $33.8M | $31.5M | $29.8M | |
| Gross profit | $19.3M | $20.2M | $21.9M | $21.7M | $20.0M | $19.3M | |
| Operating income | $4.8M | $3.2M | $4.2M | $2.1M | $1.6M | $700.0K | |
| Net income | $5.1M | $3.6M | $4.6M | $4.1M | $6.3M | $963.0K | |
| Diluted EPS | $0.06 | $0.04 | $0.05 | $0.05 | $0.07 | $0.01 | |
| Gross margin | 63.4% | 65.0% | 64.5% | 64.1% | 63.5% | 64.8% | |
| Operating margin | 15.7% | 10.2% | 12.5% | 6.2% | 5.0% | 2.4% |
Fiscal years (4-quarter sums)FY21 $67.4M · FY22 $72.1M · FY23 $83.6M · FY24 $99.6M · FY25 $129.4M
Balance sheet, Jun 30, 2026Cash & short-term investments $66.7M · Total debt $2.3M · Total assets $106.6M · Shareholders' equity $82.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 79.64M · Float 52.48M · 65.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Robert N. Fried · director, officer: Chief Executive Officer | 1.06M | 1.33% | Form 4 | Jul 8, 2026 |
| Ozan Pamir · officer: Chief Financial Officer | 13.8K | 0.02% | Form 4 | Jul 8, 2026 |
| Carlos Luis Lopez · officer: SVP, General Counsel | 4.6K | 0.01% | Form 4 | Jul 8, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 14, 2025 | Ozan Pamir | officer: Chief Financial Officer | +6,685 | $6.82 |
Peers
- Nature's Sunshine Products
Natural supplement peer with broad wellness-product overlap.
- USANA Health Sciences
Science-positioned nutrition and wellness supplement competitor.
- Nu Skin
Beauty-and-wellness seller with Pharmanex supplement overlap.
- Herbalife
Global nutrition platform competing for supplement and wellness spend.
- LifeVantage
Nutrigenomics supplement peer with aging and activation claims.
- Medifast
OPTAVIA wellness platform competing for guided health spend.
- Balchem
B2B nutrition-ingredient supplier competing with Niagen ingredients.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Niagen Bioscience | $3.30 | +0.15% | $262.0M | 17.7 | 29.5 | 2.0 | −4.3% |
| Nature's Sunshine Products | $14.21 | −0.07% | $249.9M | 14.1 | 13.2 | 0.5 | +2.0% |
| USANA Health Sciences | $14.04 | +0.07% | $259.2M | — | 13.8 | 0.3 | −5.3% |
| Nu Skin | $4.85 | +0.21% | $235.5M | — | 5.0 | 0.2 | −17.1% |
| Herbalife | $12.50 | +0.52% | $1.29B | 8.0 | 4.7 | 0.2 | +5.4% |
| LifeVantage | $6.26 | −1.11% | $80.2M | 15.9 | 17.3 | 0.4 | −23.1% |
| Medifast | $12.18 | +0.16% | $135.4M | — | — | 0.4 | −27.6% |
| Balchem | $178.44 | −0.06% | $5.73B | 35.1 | 32.1 | 5.3 | +11.2% |
| Median | 15.0 | 13.5 | 0.4 | −5.3% |